ESALY News and Press, Eisai Co. Ltd. ADR From 07/27/22

Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership PR Newswire Thomas D. Fagan Jr. Appointed Vice President, U.S. Alzheimer's Disease Commercial at Eisai Inc. NUTLEY, N.J. , July 27, 2022 /PRNewswire/ -- Eisai Inc., t...

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series TOKYO, July 26, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. The FTSE4Good Ind...

Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 TOKYO, July 26, 2022 - (JCN Newswire) - Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN24...

EISAI TO PRESENT THE LATEST LECANEMAB DATA, INCLUDING ARIA-E AND SUBCUTANEOUS FORMULATION, AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 PR Newswire TOKYO , July 25, 2022 /PRNewswire/ -- Eisai C...

A Vanderbilt University neuroscientist is throwing water on a long-held theory that beta amyloid deposits are connected to Alzheimer's disease, casting doubt on the development of many therapies in development for the condition. Speaking with the magazine Science , Matthew S...

U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab TOKYO, July 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applica...

Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing dis...

New research shows that current monoclonal antibody drugs are targeting a late stage in the amyloid hypothesis of Alzheimer’s disease. This is bad news for Biogen/Eisai, Eli Lilly, and Roche, but this opens new thoughts about Alzheimer’s disease. Biogen’s Aduh...

E.Design Insurance and Eisai Enter Into Business Alliance TOKYO, June 28, 2022 - (JCN Newswire) - E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business ...

GE Healthcare will become an independent company in the first quarter of 2023. Pharmaceutical diagnostics revenue was $487 million in Q1 2022, up 2.7% QoQ. General Electric Healthcare has one of the largest profit margins in the GE structure. GE is expanding its business by ac...